Aurobindo Pharma, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, today announced that it has closed the acquisition of Apotex's commercial operations and certain supporting infrastructure in five European countries.

The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on July 14, 2018.

This announcement does not constitute a recommendation to shareholders or potential investors.

Jefferies International acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.

Shares of the company declined Rs 0.55, or 0.07%, to trade at Rs 760.10. The total volume of shares traded was 25,043 at the BSE (10.07 a.m., Monday).